Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -4.71%73 3-Year Book Growth Rate is 12.50% as of Dec. 2025, which is 9% below its 10-year median of 13.75. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $49.96 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,136 Biotechnology companies, CSL ranks better than 79.58% on this metric.
During the past 12 months, CSL's average Book Value per Share Growth Rate was 7.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 25.50% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 26.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of CSL was 37.20% per year. The lowest was -8.90% per year. And the median was 13.75% per year.
CSL (OTCPK:CSLLY) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
CSL 3-Year Book Growth Rate Related Terms
CSLLY vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, CSL's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where CSL's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 12.50% mean?
CSL (CSLLY) has a 3-Year Book Growth Rate of 12.50% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CSL and its competitors. This is near median its historical median of 13.75. According to the industry distribution chart, CSL ranks #232 out of 1136 companies in the Biotechnology industry, placing it in the top 20.4%.
Is CSL's 3-Year Book Growth Rate too high?
CSL's current 3-Year Book Growth Rate of 12.50% is near median its 10-year median of 13.75. Based on the distribution chart, CSL ranks #232 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #232 out of 1136 companies for 3-Year Book Growth Rate. This places CSL in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CSL and its competitors. CSL's current 3-Year Book Growth Rate is 12.50%, which is near median its own 10-year median of 13.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.96, compared to a current price of $21.64 — trading 56.7% below its estimated fair value. The current 3-Year Book Growth Rate is 12.50%, which is near median its 10-year median of 13.75. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current 3-Year Book Growth Rate is 12.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.64 is trading 56.7% below its estimated GF Value™ of $49.96.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
3-Year Book Growth Rate: 12.50% (near median its 10-year median of 13.75)
GF Value™: $49.96 vs. price of $21.64 (56.7% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
